Company Filing History:
Years Active: 2022
Title: Barbara Adler: Innovator in HCMV Research
Introduction
Barbara Adler is a prominent inventor based in Munich, Germany. She has made significant contributions to the field of medical research, particularly in the development of therapies targeting human cytomegalovirus (HCMV). Her innovative work has led to the creation of a patent that holds promise for treating and preventing HCMV infections.
Latest Patents
Barbara Adler holds a patent for "HCMV entry inhibitors." The subject matter of this invention includes a soluble PDGFR-alpha-Fc chimera, a PDGFR-alpha derived peptide, an anti-PDGFR-alpha antibody, or a PDGFR-alpha antibody fragment. This invention aims to inhibit HCMV entry, providing a method of treatment for subjects infected by HCMV and a prophylactic approach for those not yet infected.
Career Highlights
Barbara Adler is associated with Aicuris Anti-infective Cures GmbH, where she continues her research and development efforts. Her work is crucial in advancing therapeutic options for HCMV, a virus that poses significant health risks, especially for immunocompromised individuals.
Collaborations
Throughout her career, Barbara has collaborated with notable colleagues, including Christian Sinzger and Cora Stegmann. These partnerships have enhanced her research and contributed to the advancement of innovative solutions in the field of anti-infective therapies.
Conclusion
Barbara Adler's contributions to HCMV research exemplify the impact of innovation in medical science. Her patent for HCMV entry inhibitors represents a significant step forward in the fight against viral infections.